Title:MSC-Derived Extracellular Vesicles against Pulmonary Fibrosis of Rodent Model: A Meta-Analysis
Volume: 20
Issue: 1
Author(s): Xinghong Zhou, Ya Liu, Jiahui Xie, Ziqi Wen, Jiaqi Yang, Hanyue Zhang, Zijing Zhou, Jinyu Zhang, Huixian Cui*Jun Ma*
Affiliation:
- Stem Cell Research Center, Hebei Medical University, Hebei Province, 050017, China
- Hebei Research Center for Stem Cell Medical Translational Engineering, Hebei Province, 050017, China
- Human Anatomy Department, Hebei Medical University, Hebei Province, 050017, China
- Stem Cell Research Center, Hebei Medical University, Hebei Province, 050017, China
- Hebei Research Center for Stem Cell Medical Translational Engineering, Hebei Province, 050017, China
- Human Anatomy Department, Hebei Medical University, Hebei Province, 050017, China
Keywords:
Pulmonary fibrosis, mesenchymal stem cell, extracellular vesicles, preclinical studies, HYP, ECM.
Abstract:
Background: Pulmonary fibrosis (PF) is a fatal disease distinguished by structural destruction
and dysfunction, accompanied by continuous accumulation of fibroblasts, which eventually leads to lung
failure. Preclinical studies have shown that the administration of mesenchymal stem cell-derived extracellular
vesicles (MSC-EVs) may be a safe and effective treatment for PF. The purpose of our meta-analysis
is to evaluate the efficacy of MSC-EVs therapy and identify therapeutic aspects related to PF.
Methods: Our study (up to April 6, 2022) identified English and Chinese, preclinical, controlled, and in
vivo studies to examine the application of MSC-EVs in the treatment of PF. The risk of bias (ROB) is
assessed using the SYRCLE bias risk tool. The primary outcomes include collagen content, α-smooth
muscle actin (α-SMA), hydroxyproline (HYP) content, and transforming growth factor-β1 (TGF-β1).
Results: Thirteen studies were included in this meta-analysis. Ten studies evaluated the collagen content,
five studies evaluated the α-SMA, five studies evaluated the HYP content, and six studies evaluated the
TGF-β1. Compared to the control group, MSC-EVs therapy was associated with a significant reduction of
collagen accumulation, α-SMA, HYP content, and TGF-β1.
Conclusion: The administration of MSC-EVs is beneficial for the treatment of rodent PF models. However,
the safety and effectiveness of the application in human PF diseases have yet to be confirmed. The
application of MSC-EVs in the treatment of PF needs to be further standardized in terms of source, route
of administration, and culture method.
